Inhibition of Atazanavir Oral Absorption by Lansoprazole Gastric Acid Suppression in Healthy Volunteers
1Schools of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York.
Patrick F. Smith, Pharm.D. 2, 1
2Schools of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York. ; Clinical Research Center, Western New York Veteran's Administration Healthcare System, Buffalo, New York.
Abayomi B. Ogundele, Pharm.D. 3,
3Schools of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York.
Robin Difrancesco, M.B.A. 4,
4Schools of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York.
Charles S. Berenson, M.D. 5,
5School of Medicine, University at Buffalo, Buffalo, New York. ; Clinical Research Center, Western New York Veteran's Administration Healthcare System, Buffalo, New York.
Ellana Eberhardt, R.N. 6,
6Clinical Research Center, Western New York Veteran's Administration Healthcare System, Buffalo, New York.
Edward Bednarczyk, Pharm.D. 7,
7Schools of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York. ; Clinical Research Center, Western New York Veteran's Administration Healthcare System, Buffalo, New York.
Gene D. Morse, Pharm.D. 8
8Schools of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York.
| Abstract |
|---|
Study Objective. To determine whether the pharmacokinetics of atazanavir, a protease inhibitor used to treat human immunodeficiency virus (HIV) infection, are altered by its coadministration with lansoprazole, a proton pump inhibitor.
Design. Single-dose, open-label, complete-crossover study.
Setting. Clinical research center.
Subjects. Ten healthy adult volunteers.
Measurements and Main Results. In phase A, subjects received a single oral dose of atazanavir 400 mg alone. In phase B, the same subjects received oral lansoprazole 60 mg, and after 24 hours they were given a second dose of oral lansoprazole 60 mg with atazanavir 400 mg. Eleven blood samples were collected from each subject over a 24-hour period for determination of atazanavir plasma concentrations by a validated high-performance liquid chromatography assay. Pharmacokinetic analysis was performed by standard noncompartmental methods. Nine subjects completed the study, and no significant adverse events were reported. Absorption of atazanavir was significantly reduced when it was coadministered with lansoprazole, as evidenced by a 94% decline in mean area under the concentration-time curve during the 24 hours after administration (AUC0–24) (p<0.01). The mean ± SD AUC0–24 for phase A was 16.3 ± 9.0 μM•hour versus 0.95 ± 1.8 μM•hour for phase B (p<0.01). The mean ± SD maximum concentration of atazanavir was 3.2 ± 1.7 μM for phase A and 0.13 ± 0.19 μM for phase B (p<0.01).
Conclusion. Acid suppression markedly reduced the bioavailability of atazanavir in this group of healthy volunteers. Based on these results, atazanavir should not be coadministered with lansoprazole or other proton pump inhibitors.
| References |
|---|
| 1. | U.S. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Available from http://aidsinfo.nih.gov/guidelines/ Accessed July 23, 2005. |
| 2. | Goldsmith DR, Perry CM. Atazanavir. Drugs 2003;63(16):1679–95. |
| 3. | Bristol-Myers Squibb. Reyataz (atazanavir sulfate) package insert. Princeton, NJ; 2005. |
| 4. | Durant J, Clevenbergh P, Garraffo R, et al. Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the viradapt study. AIDS 2000;14(10):1333–9. |
| 5. | Fletcher CV, Brundage RC, Remmel RP, et al. Pharmacologic characteristics of indinavir, didanosine, and stavudine in human immunodeficiency virus-infected children receiving combination therapy. Antimicrob Agents Chemother 2000;44(4):1029–34. |
| 6. | Kosel BW, Storey SS, Collier AC. Lack of interaction between atazanavir and lansoprazole. AIDS 2005;19(6):637–8. |
| 7. | Agarwala S, Gray K, Wang Y, Grasela D. Pharmacokinetic effect of omeprazole on atazanavir co-administered with ritonavir in healthy subjects. Presented at the 12th conference on retroviruses and opportunistic infections, Boston, MA, February 22–25, 2005. |
| 8. | Farthing C, Khanlou H. Co-administration of atazanavir with proton-pump inhibitors and H2-blockers. Presented at the 7th international congress on drug therapy in HIV infection, Glasgow, Scotland, November 14–18, 2004. |
| 9. | Keil K, Frerichs VA, DiFrancesco R, Morse G. Reverse phase high-performance liquid chromatography method for the analysis of amprenavir, efavirenz, indinavir, lopinavir, nelfinavir and its active metabolite (M8), ritonavir, and saquinavir in heparinized human plasma. Ther Drug Monit 2003;25(3):340–6. |
| 10. | Freston JW, Pilmer BL, Chiu YL, et al. Evaluation of the pharmacokinetics and pharmacodynamics of intravenous lansoprazole. Aliment Pharmacol Ther 2004;19(10):1111–22. |
| 11. | Gremse DA. Lansoprazole: pharmacokinetics, pharmacodynamics and clinical uses. Expert Opin Pharmacother 2001;2(10):1663–70. |
| 12. | Doan TT, Wang Q, Griffin JS, Lukasik NL, O'Dea RF, Pan WJ. Comparative pharmacokinetics and pharmacodynamics of lansoprazole oral capsules and suspension in healthy subjects. Am J Health-Syst Pharm 2001;58(16):1512–19. |
| 13. | Moules IK. Lansoprazole: pharmacokinetics and pharmacodynamics. Br J Clin Pract 1994;75(suppl):41–7. |
| 14. | Hussein Z, Granneman GR, Mukherjee D, et al. Age-related differences in the pharmacokinetics and pharmacodynamics of lansoprazole. Br J Clin Pharmacol 1993;36(5):391–8. |
| 15. | Luber A, Garg V, Gharakhanian S. Survey of medications used by HIV-infected patients that affect gastrointestinal (GI) acidity and potential for negative drug interactions with HAART. Presented at the 7th international congress on drug therapy in HIV infection, Glasgow, Scotland, November 14–18, 2004. |
| 16. | Shelton MJ, Adams JM, Hewitt RG, Morse GD. Previous infection with Helicobacter pylori is the primary determinant of spontaneous gastric hypoacidity in human immunodeficiency virus-infected outpatients. Clin Infect Dis 1998;27(4):739–45. |
| 17. | Shelton MJ, Adams JM, Hewitt RG, et al. Effects of spontaneous gastric hypoacidity on the pharmacokinetics of zidovudine and didanosine. Pharmacotherapy 1997;17(3):438–44. |
| 18. | Smith PF, Dicenzo R, Forrest A, et al. Population pharmacokinetics of delavirdine and N-delavirdine in HIVinfected individuals. Clin Pharmacokinet 2005;44(1):99–109. |
| 19. | Smith PF, DiCenzo R, Morse GD. Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors. Clin harmacokinet 2001;40(12):893–905. |
| 20. | Shelton MJ, Hewitt RG, Adams JM, Cox SR, Chambers JH, Morse GD. Delavirdine malabsorption in HIV-infected subjects with spontaneous gastric hypoacidity. J Clin Pharmacol Feb 2003;43(2):171–9. |
Cited by
Online publication date: 1-Mar-2011.
Abstract | PDF (157 KB) | PDF Plus (158 KB)
Online publication date: 1-Jan-2008.
Abstract | PDF (118 KB) | PDF Plus (178 KB)